Timothy Fenske
Professor of Medicine, Section Head of Hematologic Malignancies
Medical College of Wisconsin · Milwaukee, United States
Led the landmark ECOG-ACRIN EA4151 trial showing ASCT not beneficial in MRD-negative MCL patients in first CR. Note: may have relocated from Medical College of Wisconsin to UT Health San Antonio as of late 2024.
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
Bone marrow transplantation · Jun 1, 2025
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
Blood advances · Jul 9, 2024
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Clinical lymphoma, myeloma & leukemia · Apr 1, 2024